Article

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients

2023-05-11

Abstract excerpt

<title>Abstract</title> <p><bold>BACKGROUND</bold> The 21-gene assay (Oncotype DX®) can be used to guide use of chemotherapy in the management of patients with pN1 [1–3 positive lymph nodes (LNs)] breast cancer, specifically with respect to assessing potential benefit of chemotherapy. However, practice patterns based on this assay, as well as associated outcomes, have not been prospectively evaluated for pN2 (4–9...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c11afc5-43a1-5404-9ef7-61b6806c14d0
DOI: 10.21203/rs.3.rs-2793687/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsDOI 10.21203/rs.3.rs-2793687/v1Read

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.Semantic proximity Read

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database StudySemantic proximity Read

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read

21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Semantic proximity Read

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read

Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.Semantic proximity Read

Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.Semantic proximity Read

Application of a 21-Gene Recurrence Score in a Swiss Single Center Breast Cancer Population. A Comparative Analysis of Treatment Administration before and after TAILORxSemantic proximity Read

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.Semantic proximity Read